Redefining CML care at Novartis @Novartis
Redefining CML care at Novartis  @Novartis
Uploaded September 2026 | Updated November 2026, 3 hours ago
Some moments stay with you.

For Insa Gathmann, it was seeing early data in the late 1990s that suggested something unprecedented was happening. At first, it felt almost too good to be true.

Nearly three decades later, the lead biostatistician looks back on a targeted therapy that helped transform chronic myeloid leukemia treatment and redefine what was possible for many patients living with the disease.

Learn more: https://go.novartis.social/4r5lmgL
Redefining CML care at NovartisLiving with neuroendocrine cancer – meet CarolynEpisode 2: To share or not to share? That is the questionDont push changes in your MS to the back of your mind.Why does this disease stand out so strikingly?What do motorsport and heart health have in common?Simone’s storyChagas in one WordChapter 1: The evolution of cardiovascular treatment and death rateThe Beacons: Marion’s StoryLiving with neuroendocrine cancer – meet RoyTackling the myths around hiring refugees
Novartis |

Redefining CML care at Novartis

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER